The National Institute for Health and Care Excellence (NICE) has recommended Immunocore’s Kimmtrak (tebentafusp) as the first ever drug to treat patients with an aggressive form of eye cancer. Kimmtrak will now be available on the NHS in England to treat HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, with more than 100 patients expected to be eligible for the drug every year. Source: PM Live 4/12/2024